Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 May;48(5):577-585.
doi: 10.1007/s40264-024-01510-9. Epub 2025 Jan 10.

Multi-Stakeholder Call to Action for the Future of Vaccine Post-Marketing Monitoring: Proceedings from the First Beyond COVID-19 Monitoring Excellence (BeCOME) Conference

Affiliations

Multi-Stakeholder Call to Action for the Future of Vaccine Post-Marketing Monitoring: Proceedings from the First Beyond COVID-19 Monitoring Excellence (BeCOME) Conference

Vincent Bauchau et al. Drug Saf. 2025 May.
No abstract available

PubMed Disclaimer

Conflict of interest statement

Declarations. Funding: The cost of attending the conference was covered by The International Federation of Pharmaceutical Manufacturers and Associations. This cost included the use of the conference center, including meals, and accommodation (not for industry participants). Travel costs were not covered. Conflicts of Interest: Vincent Bauchau has been an employee of GSK and received travel support for the conference and owns restricted shares in the GSK group of companies as part of his past employee remuneration. Phil Bryan, Kourtney Davis, Antonella Fretta, Sarah Frise, Sonja Gandhi-Banga, Corinne Jouquelet-Royer, Alena Khromava, Lin Li, Sarah MacDonald, Lydie Marcelon, Robert Massouh, Wilhelmine Meeraus, Karen Naim, Heather Rubino, Sarah Sellers, Laurence Serradell, Laurence Torcel-Pagnon, and Jamie Wilkins are employees of pharmaceutical companies as included in their respective affiliations and each own restricted shares and received travel support for the conference. Kaatje Bollaerts, Jim Buttery, Robert Chen, Daniel R. Feiken, Hector S. Izurieta, Raj Long, and Dale Nordenberg have no competing interests to declare that are relevant to this article. Flor M. Munoz has been a data safety monitoring board member for Pfizer and Meissa, a clinical investigator for studies from Pfizer and Gilead, and an advisory board member for Sanofi, Merck, AstraZeneca, GSK, and Moderna. Hanna Nohnek has contributed to Innovatives Medicine Initiative-funded projects, is the chair of the World Health Organization Strategic Advisory Group of Experts on Immunization and a member of the Finish Institute for Health and Welfare National Immunization Technical Advisory Group. Daniel Salmon has received grant support through the stated affiliation from Merck and the Vaccine Confidence Fund and has served as a paid advisory board member for Merck and Moderna. Disclosure: These contributions represent the authors’ own best judgement. They do not bind or obligate any institution. The findings and conclusions contained within are those of the authors and do not necessarily reflect the positions or policies of the World Health Organization. Ethics Approval: Not Applicable. Consent for Publication: All authors consented for publication. Consent for Participation: Not Applicable. Availability of Data and Material: Not applicable. Code Availability: Not Applicable. Author Contributions: All authors contributed to the conceptualization, concept, and design of the manuscript. Content generation and preparation of the first draft was performed by Sonia Banga, Kaatje Bollaerts, Kourtney Davis, Robert Chen, Antonella Fretta, Sarah Frise, Corinne Jouquelet-Royer, Alena Khromava, Sarah MacDonald, Lydie Marcelon, Robert Massouh, Wilhelmine Meeraus, Karen Naim, Dale Nordenberg, Heather Rubino, Sarah Sellers, Laurence Torcel-Pagnon, and Jamie Wilkins. All authors commented on subsequent versions and approved the final manuscript.

Similar articles

Cited by

References

    1. Salmon D, Kathrine Yih W, Lee G, et al. Sources to monitor H1N1 vaccine safety points to potential for even broader safety surveillance. Health Aff. 2012;31(11):2518–27. 10.1377/hlthaff.2012.0104. - PubMed
    1. Dodd CN, Romio SA, Black S, et al. International collaboration to assess the risk of Guillain Barré Syndrome following Influenza A (H1N1) 2009 monovalent vaccines. Vaccine. 2013;31(40):4448–58. 10.1016/j.vaccine.2013.06.032. - PubMed
    1. Id.DRIVE [Internet]. 2024 [cited 2024 Nov 11]. Available from: https://iddrive.eu. Accessed 24 June 2024.
    1. Bauchau V, Davis K, Frise S, et al. Real-world monitoring of COVID-19 vaccines: an industry expert view on the successes, challenges, and future opportunities. Drug Saf. 2023;46:327–33. 10.1007/s40264-023-01290-8. - PMC - PubMed
    1. Myers TR, Marquez PL, Gee JM, et al. The v-safe after vaccination health checker: active vaccine safety monitoring during CDC’s COVID-19 pandemic response. Vaccine. 2023;41(7):1310–8. 10.1016/j.vaccine.2022.12.031. - PMC - PubMed

LinkOut - more resources